Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 77 entries
View as:

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Phase: N/A Priority: Normal
NCT ID: NCT01336829 Org: User:
Start: 03/31/11 End: 09/30/11 Due: 09/30/12

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

Phase: N/A Priority: Normal
NCT ID: NCT00115050 Org: User:
Start: 06/30/05 End: 06/30/07 Due: 06/30/08

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

Phase: N/A Priority: Normal
NCT ID: NCT00741741 Org: User:
Start: 07/31/08 End: 11/30/09 Due: 11/30/10

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

Phase: N/A Priority: Normal
NCT ID: NCT00524368 Org: User:
Start: 10/31/07 End: 10/31/11 Due: 10/31/12

TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains

Phase: N/A Priority: Normal
NCT ID: NCT00964327 Org: User:
Start: 08/31/01 End: 10/31/03 Due: 10/31/04

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Phase: N/A Priority: Normal
NCT ID: NCT00110305 Org: User:
Start: 06/30/05 End: 12/31/11 Due: 12/31/12

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT00081588 Org: User:
Start: 11/30/03 End: 12/31/08 Due: 12/31/09

TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin

Phase: N/A Priority: Normal
NCT ID: NCT01288742 Org: User:
Start: 01/31/11 End: 05/31/11 Due: 05/31/12

TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation

Phase: N/A Priority: Normal
NCT ID: NCT00812292 Org: User:
Start: 01/31/09 End: 04/30/09 Due: 04/30/10

A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT00561353 Org: User:
Start: 01/31/08 End: 05/31/10 Due: 05/31/11

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

Phase: N/A Priority: Normal
NCT ID: NCT00354627 Org: User:
Start: 01/31/06 End: 03/31/12 Due: 03/31/13

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01090648 Org: User:
Start: 03/31/10 End: 05/31/10 Due: 05/31/11

TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435

Phase: N/A Priority: Normal
NCT ID: NCT01381835 Org: User:
Start: 07/31/11 End: 01/31/12 Due: 01/31/13

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00980330 Org: User:
Start: 10/31/09 End: 08/31/11 Due: 08/31/12

A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone

Phase: N/A Priority: Normal
NCT ID: NCT00915564 Org: User:
Start: 09/30/09 End: 01/31/10 Due: 01/31/11

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT00355524 Org: User:
Start: 06/30/06 End: 03/31/11 Due: 03/31/12

TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.

Phase: N/A Priority: Normal
NCT ID: NCT00866853 Org: User:
Start: 03/31/09 End: 07/31/09 Due: 07/31/10

TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet

Phase: N/A Priority: Normal
NCT ID: NCT00752310 Org: User:
Start: 04/30/08 End: 08/31/08 Due: 08/31/09

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Phase: N/A Priority: Normal
NCT ID: NCT00254046 Org: User:
Start: 11/30/05 End: 07/31/08 Due: 07/31/09

TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir

Phase: N/A Priority: Normal
NCT ID: NCT01205139 Org: User:
Start: 11/30/10 End: 03/31/11 Due: 03/31/12

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

Phase: N/A Priority: Normal
NCT ID: NCT00838760 Org: User:
Start: 02/28/09 End: 10/31/09 Due: 10/31/10

TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing

Phase: N/A Priority: Normal
NCT ID: NCT00938899 Org: User:
Start: 01/31/07 End: 09/30/07 Due: 09/30/08

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

Phase: N/A Priority: Normal
NCT ID: NCT00110877 Org: User:
Start: 04/30/05 End: 10/31/11 Due: 10/31/12

TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light

Phase: N/A Priority: Normal
NCT ID: NCT01124799 Org: User:
Start: 07/31/10 End: 04/30/11 Due: 04/30/12

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT00543725 Org: User:
Start: 06/30/08 End: 02/29/12 Due: 02/28/13